BiotechTube

Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Conditions

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Trial Timeline

Dec 24, 2015 → Jun 3, 2021

NCT ID
NCT02625610

About Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine

Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine is a phase 3 stage product being developed by Merck for Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction. The current trial status is completed. This product is registered under clinical trial identifier NCT02625610. Target conditions include Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction.

What happened to similar drugs?

1 of 20 similar drugs in Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction were approved

Approved (1) Terminated (1) Active (18)
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
🔄Nivolumab + EverolimusOno PharmaceuticalPhase 3
🔄SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811Jiangsu Hengrui MedicinePhase 3
🔄Durvalumab + Tremelimumab + Cisplatin + Gemcitabine + Carboplatin + GemcitabineAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02625610Phase 3Completed

Competing Products

20 competing products in Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
26
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
ASP1948Astellas PharmaPhase 1
29
LenvatinibEisaiPhase 2
35
LenvatinibEisaiPhase 1
29
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
ONO-7913 + ONO-4538 + Fluorouracil + Oxaliplatin + Levofolinate + Bevacizumab + CetuximabOno PharmaceuticalPhase 1
33
SHR-4602Jiangsu Hengrui MedicinePhase 2
42
SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
40
HRS-6209 in Combination with Fulvestrant + HRS-6209 in Combination with HRS-1358 + HRS-6209 in Combination with Letrozole + HRS-6209 in Combination with HRS-8080 + HRS-6209 in Combination with HRS-1358Jiangsu Hengrui MedicinePhase 1/2
39
Camrelizumab + HAIC + TKIJiangsu Hengrui MedicinePhase 2
31
SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811Jiangsu Hengrui MedicinePhase 3
44
Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + OxaliplatinAbbViePhase 2
42